We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+15.12%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$161M
Cap. Flow
+$136M
Cap. Flow %
30.92%
Top 10 Hldgs %
58.73%
Holding
304
New
134
Increased
38
Reduced
45
Closed
43

Top Buys

Rank Stock Value
1
BOXX icon
Alpha Architect 1-3 Month Box ETF
BOXX
+$33.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.5M
3
CYTK icon
Cytokinetics
CYTK
+$17.6M
4
ROIV icon
Roivant Sciences
ROIV
+$16.6M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$15.9M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$20.8M
2
RPRX icon
Royalty Pharma
RPRX
+$17.7M
3
VKTX icon
Viking Therapeutics
VKTX
+$10.7M
4
MRK icon
Merck
MRK
+$6.62M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.34M

Sector Composition

Rank Sector Weight
1 Healthcare 68.67%
2 Communication Services 1.03%
3 Financials 0.65%
4 Materials 0.49%
5 Consumer Discretionary 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QTTB icon
26
Q32 Bio
QTTB
$490M
$3.2M 0.73%
187,567
+171,252
+1,050% +$2.36M
APLT
27
DELISTED
Applied Therapeutics
APLT
$3.1M 0.7%
+456,588
New +$2.05M
BIL icon
28
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$46.9B
$2.98M 0.68%
32,500
+500
+2% +$45.8K
PFE icon
29
Pfizer
PFE
$147B
$2.95M 0.67%
106,342
+88,942
+511% +$2.47M
VUSB icon
30
Vanguard Ultra-Short Bond ETF
VUSB
$8.92B
$2.74M 0.62%
55,206
+5,000
+10% +$247K
JPST icon
31
JPMorgan Ultra-Short Income ETF
JPST
$40.3B
$2.72M 0.62%
54,000
+5,000
+10% +$252K
SHV icon
32
iShares 0-1 Year Treasury Bond ETF
SHV
$20.6B
$2.71M 0.61%
24,500
– –
SLDB icon
33
Solid Biosciences
SLDB
$875M
$2.71M 0.61%
203,204
+202,204
+20,220% +$1.89M
USFR icon
34
WisdomTree Floating Rate Treasury Fund
USFR
$18.4B
$2.67M 0.6%
53,000
-3,000
-5% -$151K
CLRB icon
35
Cellectar Biosciences
CLRB
$20.6M
$2.56M 0.58%
21,418
-24,518
-53% -$2.66M
OABI icon
36
OmniAb
OABI
$317M
$2.45M 0.56%
451,485
-26,686
-6% -$154K
CNTA
37
DELISTED
Centessa Pharmaceuticals
CNTA
$2.34M 0.53%
+206,856
New +$1.96M
REGN icon
38
Regeneron Pharmaceuticals
REGN
$78.8B
$2.21M 0.5%
+2,300
New +$2.19M
IBIO icon
39
iBio
IBIO
$69.5M
$2.19M 0.5%
+600,000
New +$754K
CTVA icon
40
Corteva
CTVA
$51.4B
$2.16M 0.49%
37,400
-20,600
-36% -$1.06M
CERE
41
PUT
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$2.12M 0.48%
50,200
– –
XAIR icon
42
Beyond Air
XAIR
$3.97M
$2.1M 0.48%
+3,012
New +$2.07M
GH icon
43
CALL
Guardant Health
GH
$21.5B
$2.06M 0.47%
+100,000
New +$2.14M
IMVT icon
44
Immunovant
IMVT
$8.02B
$1.96M 0.45%
60,763
-73,362
-55% -$2.68M
LGND icon
45
Ligand Pharmaceuticals
LGND
$6.28B
$1.96M 0.44%
+26,800
New +$1.98M
ULST icon
46
State Street Ultra Short Term Bond ETF
ULST
$526M
$1.93M 0.44%
47,684
-13,580
-22% -$549K
SYRE icon
47
Spyre Therapeutics
SYRE
$9.14B
$1.88M 0.43%
49,500
+43,060
+669% +$1.25M
SDGR icon
48
Schrodinger
SDGR
$1.35B
$1.72M 0.39%
63,586
+61,586
+3,079% +$1.72M
ALNY icon
49
CALL
Alnylam Pharmaceuticals
ALNY
$30.2B
$1.67M 0.38%
+11,200
New +$1.87M
SPRO icon
50
Spero Therapeutics
SPRO
$72.4M
$1.59M 0.36%
926,929
-140,782
-13% -$221K
1
2
3 4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

ADAR1 Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, ADAR1 Capital Management held 304 positions worth $441M, up 58% from $280M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

ADAR1 Capital Management deployed $136M of net new capital in Q1 2024, opening 134 new positions and adding to 38 existing holdings. Its largest new stake was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 69% a quarter earlier, followed by Communication Services and Financials.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $20.8M trimmed.

  • ADAR1 Capital Management's largest Q1 2024 buy was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.
  • ADAR1 Capital Management added most to Alnylam Pharmaceuticals in Q1 2024, an estimated $28.5M increase.
  • ADAR1 Capital Management's biggest Q1 2024 reduction was Keros Therapeutics, cutting an estimated $20.8M.
  • ADAR1 Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 59% of its $441M portfolio in Q1 2024.
  • ADAR1 Capital Management opened 134 new positions and closed 43 in Q1 2024.
  • ADAR1 Capital Management's portfolio value rose 58% quarter-over-quarter to $441M.

Based on ADAR1 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.